Alaunos Therapeutics, Inc. also files under ZIOP; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Weis Holger | CEO | Grant(A) | 4K | $2.01 | $9K |
| Jul 23, 2026 | Postma Robert W | Director | Grant(A) | 8K | $1.92 | $16K |
| Jul 23, 2026 | Vieser Jaime | Director | Grant(A) | 9K | $1.92 | $17K |
| Jul 23, 2026 | Weis Holger | CEO | Grant(A) | 5K | $1.92 | $9K |
| Jul 23, 2026 | Jerman Michael Allen | Director | Grant(A) | 8K | $1.92 | $16K |
| Jun 30, 2026 | Weis Holger | Chief Executive Officer | Grant(A) | 4K | $2.26 | $9K |
| Jun 12, 2026 | Weis Holger | Chief Executive Officer | Grant(A) | 8K | $2.26 | $18K |
| May 22, 2026 | Weis Holger | Chief Executive Officer | Grant(A) | 4K | $2.37 | $9K |
| Apr 29, 2026 | Jerman Michael Allen | Director | Grant(A) | 6K | $2.59 | $16K |
| Apr 29, 2026 | Postma Robert W | Director | Grant(A) | 6K | $2.59 | $16K |
| Apr 29, 2026 | Vieser Jaime | Director | Grant(A) | 7K | $2.59 | $17K |
| Jan 12, 2026 | Jerman Michael Allen | Director | Grant(A) | 5K | $2.89 | $16K |
| Jan 12, 2026 | Vieser Jaime | Director | Grant(A) | 6K | $2.89 | $17K |
| Jan 12, 2026 | Postma Robert W | Director | Grant(A) | 6K | $2.89 | $16K |
| Nov 21, 2025 | Vieser Jaime | Director | Grant(A) | 5K | $3.16 | $17K |
| Nov 21, 2025 | Postma Robert W | Director | Grant(A) | 5K | $3.16 | $16K |
| Nov 21, 2025 | Jerman Michael Allen | Director | Grant(A) | 4K | $3.16 | $13K |
| Aug 18, 2025 | Groenewald Ferdinand | Vice President of Finance | Grant(A) | 11K | — | $0 |
| Aug 18, 2025 | Weis Holger | Chief Executive Officer, Director | Grant(A) | 14K | — | $0 |
| Aug 18, 2025 | Groenewald Ferdinand | Vice President of Finance | Grant(A) | 4K | — | $0 |
| Jul 15, 2025 | Jerman Michael Allen | Director | Grant(A) | 10K | — | $0 |
| Jul 15, 2025 | Jerman Michael Allen | Director | Grant(A) | 3K | — | $0 |
| Jul 3, 2025 | Postma Robert W | Director | Grant(A) | 6K | — | $0 |
| Jul 3, 2025 | Vieser Jaime | Director | Grant(A) | 6K | — | $0 |
| Jul 3, 2025 | Vieser Jaime | Director | Grant(A) | 3K | — | $0 |
| Jul 3, 2025 | Postma Robert W | Director | Grant(A) | 4K | — | $0 |
| Jul 2, 2025 | Weis Holger | Chief Executive Officer, Director | Grant(A) | 130K | — | $0 |
| Jun 24, 2025 | Vieser Jaime | Director | Buy(P) | 250 | $4.49 | $1K |
| Jun 24, 2025 | Postma Robert W | Director | Buy(P) | 600 | $4.49 | $3K |
| Apr 13, 2025 | Postma Robert W | Director | Grant(A) | 21K | $2.92 | $61K |
| Apr 13, 2025 | Postma Robert W | Director | Grant(A) | 21K | $2.92 | $61K |
| Apr 13, 2025 | Vieser Jaime | Director | Grant(A) | 17K | — | $0 |
| Apr 13, 2025 | Weis Holger | Director | Grant(A) | 11K | — | $0 |
| Apr 11, 2025 | Postma Robert W | Director | Buy(P) | 500 | $2.76 | $1K |
| Apr 11, 2025 | Postma Robert W | Director | Buy(P) | 500 | $2.76 | $1K |
| Mar 29, 2025 | Groenewald Ferdinand | VP, Finance | Grant(A) | 3K | — | $0 |
| Mar 29, 2025 | Lackey Melinda | Legal & Administration | Grant(A) | 1K | — | $0 |
| Mar 29, 2025 | Hogue Dale Curtis Jr. | See Remarks, Director | Grant(A) | 3K | — | $0 |
| Dec 31, 2024 | Vieser Jaime | Director | Sell(S) | 818 | $2.00 | $2K |
| Dec 31, 2024 | Vieser Jaime | Director | Sell(S) | 2K | $2.01 | $4K |
| Aug 14, 2024 | Groenewald Ferdinand | VP, Finance | Grant(A) | 2K | — | $0 |
| Aug 14, 2024 | Lackey Melinda | Legal & Administration | Grant(A) | 2K | — | $0 |
| Jun 6, 2024 | Weis Holger | Director | Grant(A) | 19K | — | $0 |
| Jun 6, 2024 | Vieser Jaime | Director | Grant(A) | 13K | — | $0 |
| Jun 6, 2024 | Postma Robert W | Director | Grant(A) | 13K | — | $0 |
| Jun 6, 2024 | Hofmeister Robert | Director | Grant(A) | 13K | — | $0 |
| Jun 6, 2024 | Weis Holger | Director | Grant(A) | 5K | — | $0 |
| Jan 20, 2024 | Hogue Dale Curtis Jr. | Interim CEO, Director | Grant(A) | 600K | — | $0 |
| Dec 29, 2023 | Hogue Dale Curtis Jr. | Director | Grant(A) | 42K | — | $0 |
| Dec 29, 2023 | Hogue Dale Curtis Jr. | Director | Grant(A) | 150K | — | $0 |
| Sep 1, 2023 | Boyle Kevin S. Sr. | Chief Executive Officer, Director | Sell(S) | 68K | $0.14 | $10K |
| Jun 6, 2023 | Postma Robert W | Director | Grant(A) | 100K | — | $0 |
| Jun 6, 2023 | Hofmeister Robert | Director | Grant(A) | 100K | — | $0 |
| Jun 6, 2023 | Thistle Mary | Director | Grant(A) | 100K | — | $0 |
| Jun 6, 2023 | Huang James | Director | Grant(A) | 100K | — | $0 |
| Jun 6, 2023 | Vieser Jaime | Director | Grant(A) | 100K | — | $0 |
| Jun 6, 2023 | Weis Holger | Director | Grant(A) | 100K | — | $0 |
| Mar 30, 2023 | Hofmeister Robert | Director | Grant(A) | 150K | — | $0 |
| Mar 30, 2023 | Hofmeister Robert | Director | Grant(A) | 17K | — | $0 |
| Mar 15, 2023 | Lackey Melinda | See Remarks | Grant(A) | 200K | — | $0 |
| Mar 15, 2023 | Srivastava Abhishek K | See Remarks | Grant(A) | 125K | — | $0 |
| Mar 15, 2023 | Wong Michael | Vice President, Finance | Grant(A) | 125K | — | $0 |
| Mar 15, 2023 | Boyle Kevin S. Sr. | Chief Executive Officer, Director | Grant(A) | 1.8M | — | $0 |
| Mar 15, 2023 | Deniger Drew | See Remarks | Grant(A) | 125K | — | $0 |
| Nov 29, 2022 | Postma Robert W | Director | Buy(P) | 750K | $0.65 | $488K |
| Nov 29, 2022 | Vieser Jaime | Director | Buy(P) | 1.3M | $0.65 | $813K |
| Sep 15, 2022 | Deniger Drew | VP, Research and Development | Grant(A) | 305K | — | $0 |
| Sep 15, 2022 | Wong Michael | VP, Finance | Grant(A) | 50K | — | $0 |
| Sep 15, 2022 | Srivastava Abhishek K | See Remarks | Grant(A) | 25K | — | $0 |
| Sep 15, 2022 | Lackey Melinda | Senior Vice President, Legal | Grant(A) | 185K | — | $0 |
| Aug 30, 2022 | Boyle Kevin S. Sr. | Chief Executive Officer, Director | Tax withholding(F) | 19K | $2.41 | $45K |
| Aug 12, 2022 | Srivastava Abhishek K | See Remarks | Grant(A) | 250K | — | $0 |
| Jun 22, 2022 | Thistle Mary | Director | Grant(A) | 40K | — | $0 |
| Jun 22, 2022 | Huang James | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Thistle Mary | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Huang James | Director | Grant(A) | 80K | — | $0 |
| Jun 22, 2022 | Postma Robert W | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Postma Robert W | Director | Grant(A) | 40K | — | $0 |
| Jun 22, 2022 | Thistle Mary | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Thistle Mary | Director | Grant(A) | 40K | — | $0 |
| Jun 22, 2022 | Huang James | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Huang James | Director | Grant(A) | 80K | — | $0 |
| Jun 22, 2022 | Postma Robert W | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Postma Robert W | Director | Grant(A) | 40K | — | $0 |
| Jun 22, 2022 | Vieser Jaime | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Vieser Jaime | Director | Grant(A) | 40K | — | $0 |
| Jun 22, 2022 | Bowden Christopher | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Bowden Christopher | Director | Grant(A) | 40K | — | $0 |
| Jun 22, 2022 | Weis Holger | Director | Grant(A) | 100K | — | $0 |
| Jun 22, 2022 | Weis Holger | Director | Grant(A) | 40K | — | $0 |
| Mar 30, 2022 | De Groot Eleanor | EVP, Operations | Grant(A) | 350K | — | $0 |
| Mar 30, 2022 | Boyle Kevin S. Sr. | Chief Executive Officer, Director | Grant(A) | 2.0M | — | $0 |
| Dec 22, 2021 | De Groot Eleanor | EVP, Operations | Sell(S) | 20K | $1.27 | $26K |
| Dec 10, 2021 | Lackey Melinda | Senior Vice President, Legal | Grant(A) | 370K | — | $0 |
| Nov 17, 2021 | Boyle Kevin S. Sr. | Chief Executive Officer, Director | Buy(P) | 9K | $1.40 | $13K |
| Nov 16, 2021 | Boyle Kevin S. Sr. | Chief Executive Officer, Director | Buy(P) | 884 | $1.40 | $1K |
| Sep 29, 2021 | Vieser Jaime | Director | Buy(P) | 100K | $1.91 | $191K |
| Sep 2, 2021 | Postma Robert W | Director | Buy(P) | 54K | $1.73 | $94K |
| Sep 2, 2021 | Hagen Heidi | Director | Buy(P) | 24K | $1.76 | $42K |
| Sep 2, 2021 | Postma Robert W | Director | Buy(P) | 21K | $1.73 | $35K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Alaunos Therapeutics, Inc., SEC CIK 0001107421. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under TCRT and shows every filing by that issuer (also filed as ZIOP).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-12. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for TCRT